Page last updated: 2024-12-05

isoserine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isoserine is an unnatural amino acid with a unique structure, possessing a hydroxyl group attached to the beta-carbon. This distinct feature distinguishes it from the naturally occurring amino acid, serine, which has a hydroxyl group on the alpha-carbon. It is commonly studied as a potential therapeutic agent due to its diverse biological activities, including its ability to inhibit enzymes involved in various metabolic pathways. Isoserine has shown promising results in preclinical studies, particularly in cancer research. For example, it has been found to exhibit anti-tumor activity by inhibiting the growth of various cancer cell lines. Additionally, its ability to modulate immune responses makes it a potential target for developing novel immunotherapeutic strategies. Its synthesis is achieved through various chemical approaches, involving reactions like the Strecker synthesis or enzymatic modifications. Researchers explore isoserine's potential in diverse areas, including its use as a building block for peptide synthesis, a probe for investigating enzyme mechanisms, and a scaffold for developing new pharmaceuticals.'

isoserine: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11267
CHEMBL ID4798809
SCHEMBL ID85839
MeSH IDM0196206

Synonyms (55)

Synonym
u7ltg62few ,
unii-u7ltg62few
2-hydroxy-3-aminopropanoic acid
propanoic acid, 3-amino-2-hydroxy-
dl-isoserine
isoserine
(s)-3-amino-2-hydroxypropionic acid
dl-isoserine, 98%
3-amino-2-hydroxypropanoic acid
FT-0656560
632-12-2
I0309
dl-3-amino-2-hydroxypropionic acid
A834276
3-amino-2-hydroxy-propanoic acid
AKOS009157084
(r)-isoserine
565-71-9
3-amino-2-hydroxypropionic acid
h-dl-isoser-oh
FT-0627881
FT-0625399
FT-0649422
SCHEMBL85839
AM82574
BP-13413
(rs)-isoserine
(2rs)-3-amino-2-hydroxypropanoic acid
2-hydroxy-.beta.-alanine
mfcd03428326
mfcd00008138
h-dl-beta-amino-alpha-hydroxypropionic acid
(dl)-isoserine
h-dl--amino--hydroxypropionic acid
SY007745
SY013665
F8885-0613
AS-35426
hydrobromicacid
dl-3-amino-2-hydroxypropanoic acid
h-dl-ise-oh
A869903
AB88677
EN300-95550
chembl4798809 ,
bdbm50563978
CS-W013682
(+/-)-isoserine
DTXSID70870737
isoserine, dl-
3-aminolactic acid
HY-W012966
SY013666
(r)-3-amino-2-hydroxypropionic acid
PD196866

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The rapid degradation and inactivation of the peptides makes it difficult to assess dose-response relationships precisely or to conduct long term incubations with cells in the presence of plasma or serum."( Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation.
Ceruso, M; Coller, BS; Kutok, JL; Prestwich, GD; Scudder, LE; Springer, KT, 1993
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium- and chloride-dependent GABA transporter 1Mus musculus (house mouse)IC50 (µMol)2,511.88990.03712.19228.5114AID1736160
Sodium- and chloride-dependent GABA transporter 2Mus musculus (house mouse)IC50 (µMol)229.08701.41255.26838.1283AID1736159
Sodium- and chloride-dependent GABA transporter 3Mus musculus (house mouse)IC50 (µMol)4.49651.54883.67618.1283AID1736158; AID1736188
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1736160Inhibition of mouse GAT1 expressed in HEK293 cell line assessed as inhibition of [3H]GABA uptake measured after 35 mins by liquid scintillation method2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
AID1736188Inhibition of mouse GAT4 expressed in HEK293 cell line assessed as inhibition of [3H]GABA uptake measured after 35 mins by liquid scintillation method2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
AID1736158Inhibition of mouse GAT3 expressed in HEK293 cell line assessed as inhibition of [3H]GABA uptake measured after 35 mins by liquid scintillation method2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
AID1736159Inhibition of mouse GAT2 expressed in HEK293 cell line assessed as inhibition of [3H]GABA uptake measured after 35 mins by liquid scintillation method2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (13.04)18.7374
1990's2 (8.70)18.2507
2000's9 (39.13)29.6817
2010's8 (34.78)24.3611
2020's1 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.58 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index30.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]